Clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders.
- AtomVie Global Radiopharma raises over $90M to Complete its New Facility Buildout
- Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility
- PBS Biotech Raises $22M to Expand Single-Use Manufacturing Products and Services for Cell Therapy Clients
- Escient Pharmaceuticals Announces $120 Million Series C Financing
- AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego
- Amneal Acquires Saol Therapeutics’ Baclofen Franchise